Royal Bank Of Canada Reiterates Neutral Rating for Fresenius Medical Care Corporation (FMS)

Royal Bank Of Canada reaffirmed their neutral rating on shares of Fresenius Medical Care Corporation (NYSE:FMS) in a report published on Tuesday, August 8th. Royal Bank Of Canada currently has a price target on the stock.

Other research analysts have also issued reports about the stock. UBS AG restated a sell rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, July 4th. DZ Bank AG reaffirmed a neutral rating on shares of Fresenius Medical Care Corporation in a report on Thursday, May 11th. BidaskClub downgraded shares of Fresenius Medical Care Corporation from a buy rating to a hold rating in a report on Monday, July 31st. Zacks Investment Research raised shares of Fresenius Medical Care Corporation from a hold rating to a buy rating and set a $54.00 price target on the stock in a report on Tuesday, July 11th. Finally, Nord/LB reaffirmed a buy rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $48.67.

Fresenius Medical Care Corporation (FMS) traded down 0.19% during midday trading on Tuesday, hitting $46.38. 101,389 shares of the stock traded hands. The company has a market cap of $28.46 billion, a P/E ratio of 20.34 and a beta of 0.47. The company’s 50 day moving average is $47.31 and its 200-day moving average is $44.97. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.53 by $0.05. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The firm had revenue of $4.47 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter last year, the firm earned $0.96 earnings per share. The company’s revenue was up 11.1% compared to the same quarter last year. On average, equities research analysts forecast that Fresenius Medical Care Corporation will post $2.33 EPS for the current fiscal year.

WARNING: “Royal Bank Of Canada Reiterates Neutral Rating for Fresenius Medical Care Corporation (FMS)” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/08/19/fresenius-medical-care-corporations-fms-neutral-rating-reaffirmed-at-royal-bank-of-canada-updated.html.

Several large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its stake in Fresenius Medical Care Corporation by 6.4% in the second quarter. Royal Bank of Canada now owns 501,694 shares of the company’s stock valued at $24,248,000 after buying an additional 30,119 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Fresenius Medical Care Corporation by 12.1% in the second quarter. Goldman Sachs Group Inc. now owns 228,756 shares of the company’s stock valued at $11,056,000 after buying an additional 24,705 shares during the last quarter. YorkBridge Wealth Partners LLC raised its stake in Fresenius Medical Care Corporation by 19.4% in the second quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock valued at $222,000 after buying an additional 749 shares during the last quarter. Stifel Financial Corp acquired a new stake in Fresenius Medical Care Corporation during the second quarter valued at about $225,000. Finally, OxFORD Asset Management LLP acquired a new stake in Fresenius Medical Care Corporation during the second quarter valued at about $2,460,000. 2.81% of the stock is owned by institutional investors.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

What are top analysts saying about Fresenius Medical Care Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius Medical Care Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit